08 June 2021 | News
The funding round will accelerate the validation of CyGenica’s proprietary technology
Image Credit: shutterstock.com
Indo-Irish Biotech Startup CyGenica has raised $1.4 million in a seed fund investment round, led by global venture capital investor SOSV. The funding round will accelerate the validation of CyGenica’s proprietary technology which enables safe, targeted and affordable intercellular drug delivery.
The current investment seed round of $1.4 million was led by venture capital investor SOSV. Other investors participating in the round included the VOYAGER Health-Tech fund, David Rowan, founder of Voyagers.io and angel investors Sharaf Yamani and Sami Mikati.
CyGenica intends to utilise the investment to accelerate the development of its disruptive drug delivery technology for genome editing, seeking to be a key partner of biopharmaceutical companies in the advancement of cutting-edge therapeutics for cancer and rare diseases to improve patient’s health and quality of life.
Dr Nusrat Sanghamitra, Co-founder and CEO, CyGenica said, "The investment will help de-risk our technology, expand our leadership team and take us significantly closer to our goal of enabling safe and targeted intracellular delivery of genetic therapies for cancer and rare diseases.”